-
公开(公告)号：KR1020120036526A
公开(公告)日：2012-04-18
申请号：KR1020100098259
申请日：2010-10-08
Applicant: 한국과학기술원 , 재단법인 지능형 바이오 시스템 설계 및 합성 연구단
CPC classification number: A61K38/10
Abstract: PURPOSE: A pharmacetuical composition containing antibacterial peptides is provided to enhance skin cell migration and regeneration rate. CONSTITUTION: A pharmaceutical composition for wound healing contains a peptide of general formula I, N-terminal- A P K A M X1 L L X2 L L X3 L Q K K G I - C-terminal) as an active ingredient. In general formula I, X1 is basic amino acid; X2 is each different basic amino acid; and X3 is one basic amino acid. The composition additionally contains pharmaceutically acceptable carrier, excipient, or diluents. A composition for promoting skin cell regeneration contains the peptide as an active ingredient.
Abstract translation: 目的：提供含有抗菌肽的药物组合物，以增强皮肤细胞迁移和再生率。 构成：作为活性成分的伤口愈合用药物组合物含有通式I，N-末端-A P K A M X1 L L X2 L L X3 L Q K K G I -C C-末端的肽。 通式Ⅰ中，X1为碱性氨基酸; X2分别是不同的碱性氨基酸; X3是一种碱性氨基酸。 该组合物另外含有药学上可接受的载体，赋形剂或稀释剂。 用于促进皮肤细胞再生的组合物含有作为活性成分的肽。
-
公开(公告)号：KR100805212B1
公开(公告)日：2008-02-21
申请号：KR1020070001591
申请日：2007-01-05
Applicant: 한국과학기술원
IPC: A61K38/16 , A61P35/00 , C07K14/435 , C07K14/46
CPC classification number: A61K38/1703 , C07K14/463
Abstract: A buforin derivative kaisin, kaisin I and kaisin II are provided to act selectively on cancer cells without acting on normal cells, thereby capable of providing an anticancer agent with excellent anti-cancer activity. An anticancer agent comprises a buforin derivative kaisin having an amino acid sequence of SEQ ID : NO. 1, a buforin derivative kaisin I having an amino acid sequence of SEQ ID : NO. 2, or a buforin derivative kaisin II having an amino acid sequence of SEQ ID : NO. 3 as an effective ingredient. The anticancer agent further comprises a pharmaceutically acceptable carrier.
Abstract translation: 提供了布福林衍生物凯辛，凯辛I和凯辛二，以不对正常细胞起作用，从而能够选择性地对癌细胞起作用，从而能够提供具有优异抗癌活性的抗癌剂。 抗癌剂包含具有SEQ ID NO：9的氨基酸序列的苦参蛋白衍生物凯辛素。 1，具有SEQ ID NO：1的氨基酸序列的buforin衍生物kaisin I。 2或具有SEQ ID NO：1的氨基酸序列的布林林衍生物凯辛素II。 3作为有效成分。 抗癌剂还包含药学上可接受的载体。
-
33.发明公开유전자 결실을 위한 선형 ＤＮＡ 단편, 이를 이용하여생물막 형성이 억제된 대장균 변이주 및 이의 제조 방법 失效一种用于基因缺失的线性DNA片段，一种用生物膜形成抑制的大肠杆菌突变体及其生产方法
公开(公告)号：KR1020060021161A
公开(公告)日：2006-03-07
申请号：KR1020040070017
申请日：2004-09-02
Applicant: 한국과학기술원
Abstract: 본 발명은 항생제 민감도와 생산물 분비 효율 및 형질전환 효율이 증가된 대장균 변이주에 관한 것으로, 상기 변이주는 생물막(biofilm)의 형성이 억제되어, 생물막에 의한 항생제와 분비물 및 외래 유전자에 대한 확산의 저해가 최소화된 것을 특징으로 한다. 본 발명에 의하여, 대장균의 유전자 조작 실험 도중의 변이주 선별 과정에 있어서, 보다 적은 양의 항생제로 원하는 변이주를 선별할 수 있고, 선별하고자 하는 변이주가 아닌 균주가 생물막을 형성하여 항생제에 내성을 보여서 선별의 효율을 떨어뜨리는 것을 방지할 수 있다. 또한, 분비물의 확산 효율이 증가됨으로써 배지 내로 분비되는 생산물의 수득률을 증가시킬 수 있다. 그리고 형질전환 효율이 증가됨으로써 유용 물질의 대량생산을 보다 용이하게 할 수 있다.
Abstract translation: 本发明是对抗生素的敏感性和产物分泌效率和转化效率是在大肠杆菌（E.coli）突变体菌株，其中所述突变是生物膜（生物膜）的形成被抑制，抗生素扩散放电和所述外源基因的抑制生物膜被增加 被最小化。 根据本发明，大肠杆菌的遗传修饰实验期间的突变体的筛选方法，和更可被选择用于与抗生素的少量所需的突变体，在非突变体菌株boyeoseo耐进行筛选，以抗生素和形成生物膜筛选 可以防止电池效率的降低。 另外，可以增加分泌物的扩散效率，从而增加分泌到培养基中的产物的产量。 通过提高转化效率，可以促进有用物质的大规模生产。
-
公开(公告)号：KR100381381B1
公开(公告)日：2003-12-31
申请号：KR1019980051563
申请日：1998-11-28
Applicant: 한국과학기술원
Abstract: PURPOSE: Recombinant plasmids having secretion signal sequence of endoxylanase from Bacillus are provided which express and secret foreign protein in transformed E. coli therewith. CONSTITUTION: A secretion signal sequence of endoxylanase fragment from plasmid, pKJX4, containing endoxylase gene from Bacillus is amplified by PCR. Recombinant plasmid, pJS101, is constructed by cloning PCR fragments into plasmid, pTrc99A, having strong trc promoter. Plasmid pJS101 contains signal sequence of endoxylanase and endoxylanase joined with PstI site. 3' end of endoxylanase has restriction sites of BamHI, XbaI, SalI, PstI and HindIII for the cloning of foreign protein. Plasmid pJS101DeltaP is constructed by removing PstI site of 3' end of endoxylanase gene for the easy introduction of foreign protein. T7 promoter containing vector, pJS301, is constructed by joining of NdeI and BamHI digested fragment from pJS101DeltaP and pET21c. Induction experiment with IPTG shows that the yield of secreted protein is at least 6% of total protein. Alkaline phosphatase is over expressed and constitutes 6.9% of total protein.
Abstract translation: 目的：提供具有来自芽孢杆菌属的木聚糖内切酶分泌信号序列的重组质粒，其在转化的大肠杆菌中表达并分泌外源蛋白质。 构成：通过PCR扩增来自质粒pKJX4的含有来自杆菌的内切酶基因的木聚糖内切酶片段的分泌信号序列。 通过将PCR片段克隆到具有强trc启动子的质粒pTrc99A中构建重组质粒pJS101。 质粒pJS101含有内切木聚糖酶的信号序列和与PstI位点连接的木聚糖内切酶。 内切木聚糖酶的3'末端具有BamHI，XbaI，SalI，PstI和HindIII的限制位点用于克隆外源蛋白。 质粒pJS101DeltaP是通过去除内切木聚糖酶基因的3'末端的PstI位点以便于引入外来蛋白质而构建的。 含有T7启动子的载体pJS301通过连接来自pJS101DeltaP和pET21c的NdeI和BamHI消化的片段构建。 用IPTG诱导实验显示分泌蛋白的产量至少为总蛋白的6％。 碱性磷酸酶过度表达并占总蛋白的6.9％。
-
公开(公告)号：KR1020030016802A
公开(公告)日：2003-03-03
申请号：KR1020010050545
申请日：2001-08-22
IPC: A61K38/17
Abstract: PURPOSE: A composition of treating diarrhea in mammals containing buforin II which is separated a Korean toad and has an antimicrobial effect against cause bacteria of diarrhea is provided. The composition exhibits high susceptibility against cause bacteria of diarrhea and kills cause bacteria by inhibition of intracellular physiological action of the diarrhea cause bacteria. CONSTITUTION: The composition for prevention and treatment of diarrhea contains 0.01 to 20% by weight of buforin II, based on the total weight of the composition. The composition is powder, a drug, a tablet or injectable formulation and can be also used as a vaccine preparation, a feed additive or a beverage additive. Daily dose of between about 400μg to 4mg/day is sufficient to treat diarrhea in mammals.
Abstract translation: 目的：提供含有buforin II的哺乳动物中腹泻的组合物，其分离为韩国蟾蜍，并且具有抵抗引起腹泻细菌的抗微生物作用。 该组合物对引起腹泻细菌的易感性高，通过抑制腹泻引起细菌的细胞内生理作用而杀死细菌。 构成：基于组合物的总重量，用于预防和治疗腹泻的组合物含有0.01-20重量％的buforin II。 组合物为粉末，药物，片剂或可注射制剂，也可用作疫苗制剂，饲料添加剂或饮料添加剂。 约400μg至4mg /天的日剂量足以治疗哺乳动物的腹泻。
-
Patent Agency Ranking
公开(公告)号：KR1020030016801A
公开(公告)日：2003-03-03
申请号：KR1020010050544
申请日：2001-08-22
IPC: A61K38/17
Abstract: PURPOSE: A composition of treating mastitis in mammals containing buforin II having an antimicrobial effect against microorganism causing mastitis of a lactating cow is provided. The composition is excellent in stability as well as mastitis treating effect, inhibits generation of antibiotic resistant strains of bacteria and repels cause bacteria. CONSTITUTION: The mastitis treating composition contains 0.01 to 20% by weight of buforin II and additionally an excipient, based on the total weight of the composition. The excipient is one or more selected from the group consisting of an aqueous ointment base material, oily ointment base material, olive oil and white bee'wax. Daily dosages of between about 8 and 80mg/day are sufficient to treat mastitis in mammals.
Abstract translation: 目的：提供一种哺乳动物治疗乳腺炎的组合物，其含有对引起乳牛的乳腺炎的微生物具有抗微生物作用的buforin II。 该组合物的稳定性以及乳腺炎治疗效果优异，抑制抗生素抗性菌株的产生并排斥引起细菌。 构成：乳房炎治疗组合物含有0.01至20重量％的buforin II，另外还包含赋形剂，基于组合物的总重量。 赋形剂是选自水性软膏基材，油性软膏剂基料，橄榄油和白色蜂蜡中的一种以上。 约8至80mg /天的日剂量足以治疗哺乳动物的乳腺炎。
-
公开(公告)号：KR1020020051124A
公开(公告)日：2002-06-28
申请号：KR1020000080607
申请日：2000-12-22
Applicant: 한국과학기술원 , 이한웅 , 주식회사 바이오비젠
IPC: C07K14/46
CPC classification number: C07K14/463 , A61K38/1703
Abstract: PURPOSE: Provided is an anti-cancer agent having Buforin and their derivatives as its active ingredient. The Buforin derivative, BUF(5-13)(RLLR)3 has amino acid sequence of RAGLQFPVGRLLRRLLRRLLR and selectively acts on cancer cells in vivo and vitro. CONSTITUTION: Buforin is characterized by as follows: having broader antibacterial spectrum than conventional antibiotics; showing selective antibacterial effect on not a host cell but a pathogen; and being mass-produced by genetic manipulation by prokaryotic microorganism. The anti-cancer agent includes the Buforin derivative, BUF(5-13)(RLLR) as an active ingredient, and a pharmaceutically acceptable carrier.
Abstract translation: 目的：提供具有Buforin及其衍生物作为其活性成分的抗癌剂。 Buforin衍生物BUF（5-13）（RLLR）3具有RAGLQFPVGRLLRRLLRRLLR的氨基酸序列，并在体内和体外选择性地作用于癌细胞。 构成：Buforin的特征如下：具有比常规抗生素更广泛的抗菌谱; 对宿主细胞但病原体显示出选择性的抗菌作用; 并通过原核微生物的遗传操作大规模生产。 抗癌剂包括Buforin衍生物，作为活性成分的BUF（5-13）（RLLR）和药学上可接受的载体。
-
公开(公告)号：KR100314721B1
公开(公告)日：2001-11-23
申请号：KR1019990001813
申请日：1999-01-21
Applicant: 주식회사 삼양제넥스 , 김 선 창 , 한국과학기술원
IPC: C07K14/435
Abstract: PURPOSE: Peptides having an antimicrobial activity are provided, which peptides have an antimicrobial activity similar to or more improved than that of conventional antimicrobial peptides, and also have a higher antimicrobial activity in the higher salt concentration. CONSTITUTION: The peptide having an antimicrobial activity has a sequence (RLLR)n, wherein n is an integer of 1 to 6, of which the 5'-terminal may further contain a glycine residue and of which the C-terminal is amidated. The peptide having an antimicrobial activity has a sequence PVGRVHRLLR, wherein of which the C-terminal is amidated. The peptides having an antimicrobial activity have the sequences of RAGLQFPVGRVHRLLRK, RKGLQKLVGRVHRLLRK, RLLRRLLRRLLRRLLRRLLR, and RAGLQFPVGRLLRRLLRRLLR, wherein of which the 5'-terminals contain a glycine residue, and of which the C-terminals are amidated.
-
公开(公告)号：KR102245274B1
公开(公告)日：2021-04-27
申请号：KR1020190010539
申请日：2019-01-28
Applicant: 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 , 한국과학기술원
Abstract: 본발명은최소유전체를갖는신규미생물의제조방법에관한것으로, 구체적으로미생물을 LB 브로쓰(broth)를포함하는배지에서 LB 브로쓰의농도감소에따라단계적으로배양하는단계를포함하는, 게놈의크기가야생형보다작은신규미생물의제조방법; 및상기방법으로제조된게놈의크기가야생형보다작은신규미생물에관한것이다. 본발명의신규미생물은작은게놈크기에도불구하고생장률, 피루베이트생산능, 단백질번역효율이높으며돌연변이발생율이낮으므로, 재조합단백질또는피루베이트생산등의산업에서유용하게활용될수 있다.
-
公开(公告)号：KR101788608B1
公开(公告)日：2017-10-24
申请号：KR1020150061691
申请日：2015-04-30
Applicant: 한국과학기술원 , 재단법인 지능형 바이오 시스템 설계 및 합성 연구단
CPC classification number: C12P33/00 , C12N9/10 , C12N9/1051 , C12P33/20 , C12Y204/01017
Abstract: 본발명은 PPD(protopanaxadiol) 또는 PPT(protopanaxatriol) 계열의진세노사이드의 20번탄소에위치한히드록실기(hydroxyl group)에대하여당전이활성을가지는, UDP-당전이효소(uridine diphosphate glycosyltransferase) 단백질및 이를이용한 UDP-당전이방법에관한것이다.
Abstract translation: 在PPD（原人参二醇）或PPT（三醇）人参碳羟基的第20号系列（羟基），它是活动的转变，转移每UDP-（尿苷二磷酸糖基转移酶）本发明涉及相对于所述蛋白质和糖 以及使用其的UDP-糖转移方法。
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.024 seconds)
